Nutriband Sells 90% Stake in Pocono Pharmaceutical for $5 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 29 2025
0mins
Source: NASDAQ.COM
- Stake Sale: Nutriband has agreed to sell a 90% stake in its subsidiary Pocono Pharmaceutical for $5 million, which will provide the company with capital to support the development of its core products.
- Continued Investment: Proceeds from the sale will be directed towards the ongoing development of AVERSA Fentanyl, which has the potential to become the world's first abuse-deterrent opioid patch, with projected annual sales ranging from $80 million to $200 million.
- Shareholder Retention: Following the transaction, Nutriband shareholders will retain a 10% stake in EarthVision Bio, ensuring continued shareholder interest and potentially providing an additional revenue stream for future growth.
- Sustainability Focus: EarthVision Bio's development of sustainable products aims to replace plastics and other traditional materials, aligning with the growing market demand for eco-friendly alternatives and enhancing Nutriband's strategic position in the sustainability sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INTC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INTC
Wall Street analysts forecast INTC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTC is 39.30 USD with a low forecast of 20.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
29 Analyst Rating
5 Buy
19 Hold
5 Sell
Hold
Current: 48.660
Low
20.00
Averages
39.30
High
52.00
Current: 48.660
Low
20.00
Averages
39.30
High
52.00
About INTC
Intel Corporation is a global designer and manufacturer of semiconductor products. The Company operates through three segments: Intel Products, Intel Foundry, and All Other. Its Intel Products segment includes Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX). The CCG is bringing together the operating system, system architecture, hardware, and software application integration to enable PC experiences. DCAI delivers workload-optimized solutions to cloud service providers and enterprises, along with silicon devices for communications service providers, network and edge, and HPC customers. NEX helps networks and edge compute systems from fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Intel Foundry segment comprises technology development, manufacturing and foundry services. All Other segments include Altera, Mobileye, Other.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intel Shares Drop After Weak Earnings Guidance
- Weak Earnings Report: Intel's Q4 revenue fell 4% year-over-year from $14.3 billion to $13.7 billion, indicating ongoing struggles with revenue growth and gross margins, which may impact investor confidence.
- Divergent Product Revenue: Client Computing Group (CCG) product revenue dropped 7% to $8.2 billion, while Data Center and AI (DCAI) product revenue rose 9% to $4.7 billion, reflecting performance disparities across different business lines.
- Margin Pressure: The company's gross margin decreased from 39.2% to 36.1%, with adjusted gross margins falling to 37.9%, highlighting challenges in cost control that could affect future profitability.
- Cautious Outlook: Intel projects Q1 revenue between $11.7 billion and $12.7 billion with breakeven adjusted EPS, falling short of analyst expectations, indicating supply constraints and competitive pressures in the market.
Continue Reading
Intel's Q4 Results Exceed Expectations but Guidance Falls Short
- Strong Performance: Intel reported non-GAAP adjusted earnings of $0.15 per share and sales of $13.7 billion in Q4, surpassing market expectations of $0.08 earnings and $13.4 billion sales, demonstrating resilience in a competitive landscape.
- Guidance Falls Short: Despite a strong Q4, Intel's Q1 sales guidance of $11.7 to $12.7 billion, with a midpoint below the $12.51 billion analyst estimate, reflects challenges in production transitions that may impact future performance.
- AI and Data Center Growth: Intel's data center and AI segment saw an 8.9% year-over-year sales increase to $4.7 billion, exceeding the $4.43 billion analyst forecast, indicating potential in emerging markets, although supply issues limited higher sales.
- Severe Foundry Losses: Intel's foundry business posted a $10.3 billion operating loss last year, and while Q1 revenue is expected to rise sequentially, low adoption rates among third-party customers suggest a lack of market confidence in this segment.
Continue Reading